Low ANXA10 expression is associated with disease aggressiveness in bladder cancer

Background: Markers for outcome prediction in bladder cancer are urgently needed. We have previously identified a molecular signature for predicting progression in non-muscle-invasive bladder cancer. ANXA10 was one of the markers included in the signature and we now validated the prognostic relevanc...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2011-10, Vol.105 (9), p.1379-1387
Main Authors: Munksgaard, P P, Mansilla, F, Brems Eskildsen, A-S, Fristrup, N, Birkenkamp-Demtröder, K, Ulhøi, B P, Borre, M, Agerbæk, M, Hermann, G G, Ørntoft, T F, Dyrskjøt, L
Format: Article
Language:English
Subjects:
692/53/2423
692/699/67/322
692/699/67/589/1336
692/700/1750
Annexins - metabolism
Biomarkers, Tumor - analysis
Biomedical and Life Sciences
Biomedicine
Bladder cancer
Cancer Research
Disease Progression
Disease-Free Survival
Down-Regulation
Drug Resistance
Epidemiology
Female
Gene Knockdown Techniques
Humans
Male
Middle Aged
Molecular Diagnostics
Molecular Medicine
Neoplasm Invasiveness
Neoplastic Cells, Circulating
Oncology
Prognosis
Urinary Bladder Neoplasms - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c473t-ff012da1db7999b5a90217b579aa8bcc678f1f47dfb3c76f7c2a7db395b6ab133
cites cdi_FETCH-LOGICAL-c473t-ff012da1db7999b5a90217b579aa8bcc678f1f47dfb3c76f7c2a7db395b6ab133
container_end_page 1387
container_issue 9
container_start_page 1379
container_title British journal of cancer
container_volume 105
creator Munksgaard, P P
Mansilla, F
Brems Eskildsen, A-S
Fristrup, N
Birkenkamp-Demtröder, K
Ulhøi, B P
Borre, M
Agerbæk, M
Hermann, G G
Ørntoft, T F
Dyrskjøt, L
description Background: Markers for outcome prediction in bladder cancer are urgently needed. We have previously identified a molecular signature for predicting progression in non-muscle-invasive bladder cancer. ANXA10 was one of the markers included in the signature and we now validated the prognostic relevance of ANXA10 at the protein level. Methods: We investigated ANXA10 expression by immunohistochemistry using a tissue microarray with 249 Ta and T1 urothelial carcinomas. The expression of ANXA10 was also investigated in an additional set of 97 more advanced tumours. The functional role of ANXA10 in cell lines was investigated by siRNA-mediated ANXA10 knockdown using wound-healing assays, proliferation assays, and ingenuity pathway analysis. Results: Low expression of ANXA10 correlated with shorter progression-free survival in patients with stage Ta and T1 tumours ( P
doi_str_mv 10.1038/bjc.2011.404
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3241563</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>900775952</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-ff012da1db7999b5a90217b579aa8bcc678f1f47dfb3c76f7c2a7db395b6ab133</originalsourceid><addsrcrecordid>eNp10c1LHDEYBvAgFV21N88SeunF2SaZj0wuhUWqLSyWQoXewpuPWbPMJttkRtv_3kxXtx_QUwjvjycfD0LnlMwpKdt3aq3njFA6r0h1gGa0LllBW8ZfoRkhhBdEMHKMTlJa560gLT9Cx4wKLirGZujLMjzixe23BSXY_thGm5ILHruEIaWgHQzW4Ec33GPjkoVkMaxWv9SD9XnBzmPVgzE2Yg1e23iGDjvok339vJ6iu-sPX68-FsvPN5-uFstCV7wciq4jlBmgRnEhhKpBEEa5qrkAaJXWDW872lXcdKrUvOm4ZsCNKkWtGlC0LE_R-13udlQba7T1Q4RebqPbQPwpAzj598S7e7kKD7JkFa2bKeDtc0AM30ebBrlxSdu-B2_DmKTIv8drUbMs3_wj12GMPr9uQlUmrMnocod0DClF2-2vQomcmpK5KTk1JXNTmV_8ef09fqkmg2IHUh75lY2_D_1PIN55D8MY7T4wo8lM5Ako-ql1</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>900495226</pqid></control><display><type>article</type><title>Low ANXA10 expression is associated with disease aggressiveness in bladder cancer</title><source>PubMed</source><creator>Munksgaard, P P ; Mansilla, F ; Brems Eskildsen, A-S ; Fristrup, N ; Birkenkamp-Demtröder, K ; Ulhøi, B P ; Borre, M ; Agerbæk, M ; Hermann, G G ; Ørntoft, T F ; Dyrskjøt, L</creator><creatorcontrib>Munksgaard, P P ; Mansilla, F ; Brems Eskildsen, A-S ; Fristrup, N ; Birkenkamp-Demtröder, K ; Ulhøi, B P ; Borre, M ; Agerbæk, M ; Hermann, G G ; Ørntoft, T F ; Dyrskjøt, L</creatorcontrib><description>Background: Markers for outcome prediction in bladder cancer are urgently needed. We have previously identified a molecular signature for predicting progression in non-muscle-invasive bladder cancer. ANXA10 was one of the markers included in the signature and we now validated the prognostic relevance of ANXA10 at the protein level. Methods: We investigated ANXA10 expression by immunohistochemistry using a tissue microarray with 249 Ta and T1 urothelial carcinomas. The expression of ANXA10 was also investigated in an additional set of 97 more advanced tumours. The functional role of ANXA10 in cell lines was investigated by siRNA-mediated ANXA10 knockdown using wound-healing assays, proliferation assays, and ingenuity pathway analysis. Results: Low expression of ANXA10 correlated with shorter progression-free survival in patients with stage Ta and T1 tumours ( P &lt;0.00001). Furthermore, patients with more advanced tumours and low ANXA10 expression had an unfavourable prognosis ( P &lt;0.00001). We found that ANXA10 siRNA transfected cells grew significantly faster compared with control siRNA transfected cells. Furthermore, a wound-healing assay showed that ANXA10 siRNA transfected cells spread along wound edges faster than control transfected cells. Conclusion: We conclude that ANXA10 may be a clinical relevant marker for predicting outcome in both early and advanced stages of bladder cancer.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.2011.404</identifier><identifier>PMID: 21979422</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/53/2423 ; 692/699/67/322 ; 692/699/67/589/1336 ; 692/700/1750 ; Annexins - metabolism ; Biomarkers, Tumor - analysis ; Biomedical and Life Sciences ; Biomedicine ; Bladder cancer ; Cancer Research ; Disease Progression ; Disease-Free Survival ; Down-Regulation ; Drug Resistance ; Epidemiology ; Female ; Gene Knockdown Techniques ; Humans ; Male ; Middle Aged ; Molecular Diagnostics ; Molecular Medicine ; Neoplasm Invasiveness ; Neoplastic Cells, Circulating ; Oncology ; Prognosis ; Urinary Bladder Neoplasms - metabolism</subject><ispartof>British journal of cancer, 2011-10, Vol.105 (9), p.1379-1387</ispartof><rights>The Author(s) 2011</rights><rights>Copyright Nature Publishing Group Oct 25, 2011</rights><rights>Copyright © 2011 Cancer Research UK 2011 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-ff012da1db7999b5a90217b579aa8bcc678f1f47dfb3c76f7c2a7db395b6ab133</citedby><cites>FETCH-LOGICAL-c473t-ff012da1db7999b5a90217b579aa8bcc678f1f47dfb3c76f7c2a7db395b6ab133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241563/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241563/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21979422$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Munksgaard, P P</creatorcontrib><creatorcontrib>Mansilla, F</creatorcontrib><creatorcontrib>Brems Eskildsen, A-S</creatorcontrib><creatorcontrib>Fristrup, N</creatorcontrib><creatorcontrib>Birkenkamp-Demtröder, K</creatorcontrib><creatorcontrib>Ulhøi, B P</creatorcontrib><creatorcontrib>Borre, M</creatorcontrib><creatorcontrib>Agerbæk, M</creatorcontrib><creatorcontrib>Hermann, G G</creatorcontrib><creatorcontrib>Ørntoft, T F</creatorcontrib><creatorcontrib>Dyrskjøt, L</creatorcontrib><title>Low ANXA10 expression is associated with disease aggressiveness in bladder cancer</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background: Markers for outcome prediction in bladder cancer are urgently needed. We have previously identified a molecular signature for predicting progression in non-muscle-invasive bladder cancer. ANXA10 was one of the markers included in the signature and we now validated the prognostic relevance of ANXA10 at the protein level. Methods: We investigated ANXA10 expression by immunohistochemistry using a tissue microarray with 249 Ta and T1 urothelial carcinomas. The expression of ANXA10 was also investigated in an additional set of 97 more advanced tumours. The functional role of ANXA10 in cell lines was investigated by siRNA-mediated ANXA10 knockdown using wound-healing assays, proliferation assays, and ingenuity pathway analysis. Results: Low expression of ANXA10 correlated with shorter progression-free survival in patients with stage Ta and T1 tumours ( P &lt;0.00001). Furthermore, patients with more advanced tumours and low ANXA10 expression had an unfavourable prognosis ( P &lt;0.00001). We found that ANXA10 siRNA transfected cells grew significantly faster compared with control siRNA transfected cells. Furthermore, a wound-healing assay showed that ANXA10 siRNA transfected cells spread along wound edges faster than control transfected cells. Conclusion: We conclude that ANXA10 may be a clinical relevant marker for predicting outcome in both early and advanced stages of bladder cancer.</description><subject>692/53/2423</subject><subject>692/699/67/322</subject><subject>692/699/67/589/1336</subject><subject>692/700/1750</subject><subject>Annexins - metabolism</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Bladder cancer</subject><subject>Cancer Research</subject><subject>Disease Progression</subject><subject>Disease-Free Survival</subject><subject>Down-Regulation</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Gene Knockdown Techniques</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Molecular Diagnostics</subject><subject>Molecular Medicine</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplastic Cells, Circulating</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Urinary Bladder Neoplasms - metabolism</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp10c1LHDEYBvAgFV21N88SeunF2SaZj0wuhUWqLSyWQoXewpuPWbPMJttkRtv_3kxXtx_QUwjvjycfD0LnlMwpKdt3aq3njFA6r0h1gGa0LllBW8ZfoRkhhBdEMHKMTlJa560gLT9Cx4wKLirGZujLMjzixe23BSXY_thGm5ILHruEIaWgHQzW4Ec33GPjkoVkMaxWv9SD9XnBzmPVgzE2Yg1e23iGDjvok339vJ6iu-sPX68-FsvPN5-uFstCV7wciq4jlBmgRnEhhKpBEEa5qrkAaJXWDW872lXcdKrUvOm4ZsCNKkWtGlC0LE_R-13udlQba7T1Q4RebqPbQPwpAzj598S7e7kKD7JkFa2bKeDtc0AM30ebBrlxSdu-B2_DmKTIv8drUbMs3_wj12GMPr9uQlUmrMnocod0DClF2-2vQomcmpK5KTk1JXNTmV_8ef09fqkmg2IHUh75lY2_D_1PIN55D8MY7T4wo8lM5Ako-ql1</recordid><startdate>20111025</startdate><enddate>20111025</enddate><creator>Munksgaard, P P</creator><creator>Mansilla, F</creator><creator>Brems Eskildsen, A-S</creator><creator>Fristrup, N</creator><creator>Birkenkamp-Demtröder, K</creator><creator>Ulhøi, B P</creator><creator>Borre, M</creator><creator>Agerbæk, M</creator><creator>Hermann, G G</creator><creator>Ørntoft, T F</creator><creator>Dyrskjøt, L</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20111025</creationdate><title>Low ANXA10 expression is associated with disease aggressiveness in bladder cancer</title><author>Munksgaard, P P ; Mansilla, F ; Brems Eskildsen, A-S ; Fristrup, N ; Birkenkamp-Demtröder, K ; Ulhøi, B P ; Borre, M ; Agerbæk, M ; Hermann, G G ; Ørntoft, T F ; Dyrskjøt, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-ff012da1db7999b5a90217b579aa8bcc678f1f47dfb3c76f7c2a7db395b6ab133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>692/53/2423</topic><topic>692/699/67/322</topic><topic>692/699/67/589/1336</topic><topic>692/700/1750</topic><topic>Annexins - metabolism</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Bladder cancer</topic><topic>Cancer Research</topic><topic>Disease Progression</topic><topic>Disease-Free Survival</topic><topic>Down-Regulation</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Gene Knockdown Techniques</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Molecular Diagnostics</topic><topic>Molecular Medicine</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplastic Cells, Circulating</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Urinary Bladder Neoplasms - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Munksgaard, P P</creatorcontrib><creatorcontrib>Mansilla, F</creatorcontrib><creatorcontrib>Brems Eskildsen, A-S</creatorcontrib><creatorcontrib>Fristrup, N</creatorcontrib><creatorcontrib>Birkenkamp-Demtröder, K</creatorcontrib><creatorcontrib>Ulhøi, B P</creatorcontrib><creatorcontrib>Borre, M</creatorcontrib><creatorcontrib>Agerbæk, M</creatorcontrib><creatorcontrib>Hermann, G G</creatorcontrib><creatorcontrib>Ørntoft, T F</creatorcontrib><creatorcontrib>Dyrskjøt, L</creatorcontrib><collection>SpringerOpen(OpenAccess)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Munksgaard, P P</au><au>Mansilla, F</au><au>Brems Eskildsen, A-S</au><au>Fristrup, N</au><au>Birkenkamp-Demtröder, K</au><au>Ulhøi, B P</au><au>Borre, M</au><au>Agerbæk, M</au><au>Hermann, G G</au><au>Ørntoft, T F</au><au>Dyrskjøt, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low ANXA10 expression is associated with disease aggressiveness in bladder cancer</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2011-10-25</date><risdate>2011</risdate><volume>105</volume><issue>9</issue><spage>1379</spage><epage>1387</epage><pages>1379-1387</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Background: Markers for outcome prediction in bladder cancer are urgently needed. We have previously identified a molecular signature for predicting progression in non-muscle-invasive bladder cancer. ANXA10 was one of the markers included in the signature and we now validated the prognostic relevance of ANXA10 at the protein level. Methods: We investigated ANXA10 expression by immunohistochemistry using a tissue microarray with 249 Ta and T1 urothelial carcinomas. The expression of ANXA10 was also investigated in an additional set of 97 more advanced tumours. The functional role of ANXA10 in cell lines was investigated by siRNA-mediated ANXA10 knockdown using wound-healing assays, proliferation assays, and ingenuity pathway analysis. Results: Low expression of ANXA10 correlated with shorter progression-free survival in patients with stage Ta and T1 tumours ( P &lt;0.00001). Furthermore, patients with more advanced tumours and low ANXA10 expression had an unfavourable prognosis ( P &lt;0.00001). We found that ANXA10 siRNA transfected cells grew significantly faster compared with control siRNA transfected cells. Furthermore, a wound-healing assay showed that ANXA10 siRNA transfected cells spread along wound edges faster than control transfected cells. Conclusion: We conclude that ANXA10 may be a clinical relevant marker for predicting outcome in both early and advanced stages of bladder cancer.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>21979422</pmid><doi>10.1038/bjc.2011.404</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-0920
ispartof British journal of cancer, 2011-10, Vol.105 (9), p.1379-1387
issn 0007-0920
1532-1827
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3241563
source PubMed
subjects 692/53/2423
692/699/67/322
692/699/67/589/1336
692/700/1750
Annexins - metabolism
Biomarkers, Tumor - analysis
Biomedical and Life Sciences
Biomedicine
Bladder cancer
Cancer Research
Disease Progression
Disease-Free Survival
Down-Regulation
Drug Resistance
Epidemiology
Female
Gene Knockdown Techniques
Humans
Male
Middle Aged
Molecular Diagnostics
Molecular Medicine
Neoplasm Invasiveness
Neoplastic Cells, Circulating
Oncology
Prognosis
Urinary Bladder Neoplasms - metabolism
title Low ANXA10 expression is associated with disease aggressiveness in bladder cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T17%3A24%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low%20ANXA10%20expression%20is%20associated%20with%20disease%20aggressiveness%20in%20bladder%20cancer&rft.jtitle=British%20journal%20of%20cancer&rft.au=Munksgaard,%20P%20P&rft.date=2011-10-25&rft.volume=105&rft.issue=9&rft.spage=1379&rft.epage=1387&rft.pages=1379-1387&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.2011.404&rft_dat=%3Cproquest_pubme%3E900775952%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c473t-ff012da1db7999b5a90217b579aa8bcc678f1f47dfb3c76f7c2a7db395b6ab133%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=900495226&rft_id=info:pmid/21979422&rfr_iscdi=true